TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC
JOURNAL OF THORACIC ONCOLOGY(2022)
关键词
LAG-3,NSCLC,PD-1/PD-L1 refractory
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要